At close: December 13 at 4:00:01 PM EST
After hours: December 13 at 4:08:40 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 1 | 7 | 11 |
| Avg. Estimate | -0.7 | -0.6 | -2.56 | -1.82 |
| Low Estimate | -0.79 | -0.6 | -2.92 | -2.54 |
| High Estimate | -0.48 | -0.6 | -2.26 | -1.07 |
| Year Ago EPS | -0.98 | -0.55 | -3.46 | -2.56 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 1 | 14 | 15 |
| Avg. Estimate | 108.86M | 112.3M | 393.19M | 584.07M |
| Low Estimate | 104.5M | 112.3M | 365M | 480M |
| High Estimate | 114.47M | 112.3M | 404.39M | 666.9M |
| Year Ago Sales | 65.83M | 87.15M | 266.72M | 393.19M |
| Sales Growth (year/est) | 65.36% | 28.86% | 47.42% | 48.55% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.87 | -0.92 | -0.73 | -0.78 |
| EPS Actual | -0.98 | -0.55 | -0.82 | -0.42 |
| Difference | -0.11 | 0.37 | -0.09 | 0.36 |
| Surprise % | -12.53% | 40.50% | -12.02% | 46.34% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.7 | -0.6 | -2.56 | -1.82 |
| 7 Days Ago | -0.73 | -0.6 | -2.62 | -1.87 |
| 30 Days Ago | -0.8 | -0.58 | -3.02 | -1.96 |
| 60 Days Ago | -0.78 | -0.55 | -3 | -1.9 |
| 90 Days Ago | -0.78 | -0.55 | -2.98 | -1.89 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 1 | 1 |
| Up Last 30 Days | 5 | -- | 7 | 5 |
| Down Last 7 Days | -- | 1 | -- | -- |
| Down Last 30 Days | 1 | 1 | -- | 3 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ZLAB | 28.97% | -9.09% | 26.06% | 28.84% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight | 10/25/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 10/21/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 8/7/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 7/12/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 7/1/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 6/25/2024 |
Related Tickers
BGNE BeiGene, Ltd.
179.35
-0.51%
LEGN Legend Biotech Corporation
35.12
-1.04%
DNLI Denali Therapeutics Inc.
22.97
-2.13%
ACLX Arcellx, Inc.
83.80
+0.46%
RCUS Arcus Biosciences, Inc.
16.08
-6.29%
KYMR Kymera Therapeutics, Inc.
42.13
-0.09%
APGE Apogee Therapeutics, Inc.
44.50
+0.41%
IMAB I-Mab
1.0000
0.00%
CNTA Centessa Pharmaceuticals plc
16.57
-1.78%
IMMP Immutep Limited
2.1800
-2.46%